GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Capex-to-Operating-Income

Lin BioScience (ROCO:6696) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Lin BioScience's Capital Expenditure for the six months ended in Jun. 2023 was NT$0.00 Mil. Its Operating Income for the six months ended in Jun. 2023 was NT$-455.47 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Lin BioScience Capex-to-Operating-Income Historical Data

The historical data trend for Lin BioScience's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience Capex-to-Operating-Income Chart

Lin BioScience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Lin BioScience Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lin BioScience's Capex-to-Operating-Income

For the Biotechnology subindustry, Lin BioScience's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lin BioScience's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lin BioScience's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Lin BioScience's Capex-to-Operating-Income falls into.



Lin BioScience Capex-to-Operating-Income Calculation

Lin BioScience's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.965) / -1096.827
=N/A

Lin BioScience's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -455.467
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lin BioScience  (ROCO:6696) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Lin BioScience Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Lin BioScience's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Lin BioScience (ROCO:6696) Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines